Dataset Viewer
Auto-converted to Parquet Duplicate
trial_id
stringlengths
11
11
source
stringclasses
3 values
subsidiary
stringlengths
2
68
sponsor
stringlengths
2
105
official_title
stringlengths
16
598
success_prediction
float64
0
1
economic_effect
float64
0
1
duration_prediction
float64
-6.13
18.5k
success_composite
float64
0.01
1
NCT00000145
listed
Bausch & Lomb Incorporated
Bausch & Lomb Incorporated
Age-Related Eye Disease Study (Areds)
0.91
0.52
2,626
0.760205
NCT00000382
listed
Rochester
University of Rochester
Preventive Intervention For Maltreated Infants
0.93
0.49
1,307
0.763312
NCT00000394
listed
GW
George Washington University
A Controlled Trial Of Acupuncture For Carpal Tunnel Syndrome
0.74
0.38
4,942
0.572433
NCT00000395
listed
UAB "AGA"
University of Alabama at Birmingham
Mechanisms Of Antifolate Efficacy In Arthritis
0.93
0.56
6,253
0.735272
NCT00000407
listed
UAB "AGA"
University of Alabama at Birmingham
Improving Vocational Outcomes In Arthritis
0.79
0.4
5,908
0.60251
NCT00000412
delisted
Merck Sharp & Dohme L.L.C.
Merck Sharp & Dohme LLC
Prevention Of Osteoporosis After Cardiac Transplantation
0.93
0.61
880
0.809563
NCT00000460
listed
UAB "AGA"
University of Alabama at Birmingham
Training Levels Comparison (Tlc) Trial In Patients With Coronary Heart Disease
0.09
0.03
5,915
0.033017
NCT00000497
listed
United HealthCare of Mississippi, Inc
University of Mississippi Medical Center
null
0.93
0.5
1,062
0.769593
NCT00000572
listed
Intermountain Medical Group, Inc
Intermountain Health Care, Inc.
Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome
0.91
0.54
2,569.88
0.784992
NCT00000577
listed
Hershey Outpatient Surgery Center, L.P.
Milton S. Hershey Medical Center
Asthma Clinical Research Network (Acrn)
0.13
0.45
6,291
0.258939
NCT00000625
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Double-Blind Phase Ii/Iii Trial Of Monotherapy Vs. Combination Therapy With Nucleoside Analogs In Hiv-Infected Persons With Cd4 Cells Of 200-500/Mm3
0.95
0.77
1,095
0.855402
NCT00000626
listed
Amgen
Amgen
Phase Ii Study Of Filgrastim (G-Csf) Plus Abvd In The Treatment Of Hiv-Associated Hodgkin'S Disease
0.94
0.54
1,095
0.771031
NCT00000627
listed
Pfizer
Pfizer
Pilot Study To Determine The Feasibility Of Fluconazole For Induction Treatment And Suppression Of Relapse Of Histoplasmosis In Patients With The Acquired Immunodeficiency Syndrome
0.94
0.58
8,036
0.695482
NCT00000635
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Treatment Of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease In Patients With Aids: Open Label Pilot Study Of Topical Trifluridine
0.93
0.53
8,036
0.672679
NCT00000637
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized Comparative Trial Of Zidovudine (Azt) Versus 2',3'-Dideoxyinosine (Ddi) Versus Azt Plus Ddi In Symptomatic Hiv-Infected Children
0.95
0.75
8,036
0.820722
NCT00000638
listed
Lederle S.L.
Lederle Laboratories
Prophylaxis Against Tuberculosis (Tb) In Patients With Human Immunodeficiency Virus (Hiv) Infection And Confirmed Latent Tuberculous Infection
0.94
0.55
8,036
0.68522
NCT00000640
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase Iii Comparative Study Of Dapsone / Trimethoprim And Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole In The Treatment Of Mild-To-Moderate Pcp In Patients With Aids
0.94
0.57
8,037
0.753449
NCT00000644
listed
Abbott
Abbott
A Phase Ii Safety And Efficacy Study Of Clarithromycin In The Treatment Of Disseminated M. Avium Complex (Mac) Infections In Patients With Aids
0.92
0.53
4,133
0.731175
NCT00000651
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Double Blind, Comparative Study Of Dideoxycytidine (Ddc) Alone Or Ddc/Azt Combination Versus Zidovudine (Zdv) Alone In Patients With Hiv Infection Who Have Received Prior Zdv Therapy
0.94
0.57
8,036
0.753453
NCT00000655
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Double-Blind Study Of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) For The Treatment Of Pneumocystis Carinii Pneumonia In Aids Patients
0.92
0.54
1,095
0.75963
NCT00000656
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase I/Ii, Open Label Study To Evaluate The Antiviral Potential Of Combination Zidovudine And 2' 3'-Dideoxyinosine (Didanosine) In Patients With Asymptomatic Hiv Disease
0.95
0.76
8,037
0.780286
NCT00000657
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Comparison Of 2',3'-Dideoxyinosine (Didanosine, Ddi) And Zidovudine In Therapy Of Patients With The Aids Dementia Complex
0.95
0.73
8,037
0.796336
NCT00000658
delisted
Schering-Plough A/S
Schering-Plough
A Phase Iii Randomized Trial Of Low-Dose Versus Standard-Dose Mbacod Chemotherapy With Rgm-Csf For Treatment Of Aids-Associated Non-Hodgkin'S Lymphoma
0.95
0.54
8,037
0.748888
NCT00000659
listed
BIOGEN INC
Biogen
A Phase Ii Trial Of Rscd4 And Azt In Patients With Aids Or Advanced Aids Related Complex (Arc)
0.08
0.1
4,150
0.105132
NCT00000660
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
Phase I Study Of Weekly Oral Vp-16 For Aids-Associated Kaposi'S Sarcoma
0.94
0.62
8,037
0.726699
NCT00000662
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Treatment Ind For Retrovir Brand Zidovudine (Azt) Therapy Of Pediatric Patients With Hiv Disease
0.79
0.06
6,208
0.440818
NCT00000667
listed
Protein Sciences Corp.
Protein Sciences Corporation
A Phase I/Ii Dose Escalation Study Of Intradermal Gp160 To Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses And Immunogenicity In Asymptomatic Hiv Seropositive Patients With More Than 400 Cd4+ Cells
0.92
0.23
8,037
0.585464
NCT00000669
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase I Safety And Pharmacokinetics Study Of 2',3'-Dideoxyinosine (Ddi) Administered Twice Daily To Infants And Children With Aids Or Symptomatic Hiv Infection
0.92
0.58
3,220
0.72802
NCT00000671
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase Ii Efficacy Study Comparing 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) And Zidovudine Therapy Of Patients With Hiv Infection Who Have Been On Long Term Zidovudine Treatment
0.93
0.57
4,150
0.750452
NCT00000672
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
An Efficacy Study Of 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) Administered Orally Twice Daily To Zidovudine Intolerant Patients With Aids Or Aids-Related Complex
0.93
0.57
4,150
0.750452
NCT00000674
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Pilot Study Of Oral Clindamycin And Pyrimethamine For The Treatment Of Toxoplasmic Encephalitis In Patients With Aids
0.94
0.54
4,581
0.699422
NCT00000676
listed
Pfizer
Pfizer
Randomized Comparative Study Of Fluconazole Versus Clotrimazole Troches In The Prevention Of Serious Fungal Infection In Patients With Aids Or Advanced Aids-Related Complex. (A Nested Study Of Actg 081)
0.95
0.6
8,036
0.769415
NCT00000677
delisted
Schering-Plough A/S
Schering-Plough
Sch 39304 As Therapy For Acute Cryptococcal Meningitis In Hiv-Infected Patients Followed By Maintenance Therapy
0.92
0.52
2,061
0.716602
NCT00000686
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase I Safety Study Of Bmy-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [D4T]) Administered Four Times Daily To Azt-Intolerant Patients With Aids Or Aids-Related Complex
0.07
0.23
3,220
0.123745
NCT00000721
listed
BIOGEN INC
Biogen
An Escalating Dose Tolerance Trial Of Bg8962 (Rcd4) In Patients Who Are Hiv Antibody Positive
0.92
0.33
731
0.666348
NCT00000737
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase I/Ii Study To Evaluate Single Agent And Combination Therapy With Megestrol Acetate And Dronabinol For The Treatment Of Hiv-Wasting Syndrome
0.93
0.64
3,219
0.75425
NCT00000738
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Randomized, Double-Blind, Placebo-Controlled Trial Of Nimodipine For The Neurological Manifestations Of Hiv-1
0.95
0.57
8,038
0.715294
NCT00000741
listed
Upjohn Inc
Upjohn
A Controlled Randomized Trial To Study The Efficacy Of Adjunctive Methylprednisolone For The Treatment Of Pneumocystis Carinii Pneumonia (Pcp) In Pediatric Aids Patients
0.12
0.09
8,038
0.121806
NCT00000742
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase I Concentration-Controlled Trial To Assess The Safety, Tolerance, Pharmacokinetics And Development Of Decreased Hiv-1 Susceptibility To The Combination Of Atevirdine Mesylate (U-87201E), Zidovudine (Azt), And Didanosine (Ddi)
0.95
0.53
8,038
0.701612
NCT00000743
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase I, Dose-Escalating Safety And Tolerance Study Of Scd4-Pe40 In Hiv-Infected Persons
0.93
0.55
731
0.747298
NCT00000744
listed
Pfizer
Pfizer
A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo For Primary And Secondary Prophylaxis Of Mucosal Candidiasis In Hiv-Infected Women
0.93
0.61
8,037
0.700038
NCT00000745
listed
Protein Sciences Corp.
Protein Sciences Corporation
A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160
0.92
0.19
8,038
0.571559
NCT00000748
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Comparative, Prospective Study Of Daily Trimethoprim / Sulfamethoxazole (Tms) And Thrice-Weekly Tms For Prophylaxis Against Pcp In Hiv-Infected Patients
0.94
0.55
1,062
0.792395
NCT00000750
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase Iii Study To Evaluate The Safety, Tolerance, And Efficacy Of Early Treatment With Zidovudine (Azt) In Asymptomatic Infants With Hiv Infection
0.94
0.53
1,062
0.785555
NCT00000752
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Management Of Hiv-Infected Patients At Risk Of Recurrent Purulent Sinusitis: Role Of Anti-Inflammatory, Antibacterial, And Decongestant Prophylaxis
0.13
0.42
8,031
0.222872
NCT00000753
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase I Concentration-Targeted Multidose Study Of Atevirdine Mesylate ( U-87201E ), Azt, And Ddi Or Ddc
0.95
0.55
731
0.758699
NCT00000754
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized Phase Ii Study Of Two Doses Of Interferon Alfa-2A (Ifn Alfa-2A) In Combination With Zidovudine (Azt) And Dideoxycytidine (Ddc) Versus Azt And Ddc Only In Patients With Hiv Infection And Less Than 400 Cd4 Cells/Mm3
0.95
0.57
8,038
0.741605
NCT00000755
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase I/Ii Trial Of Vaccine Therapy Of Hiv-1 Infected Individuals With 50-500 Cd4 Cells/Mm3
0.94
0.58
8,038
0.713013
NCT00000757
listed
Protein Sciences Corp.
Protein Sciences Corporation
A Phase I Multicenter Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160
0.92
0.18
8,038
0.568083
NCT00000765
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Pilot Study To Evaluate The Efficacy Of Zidovudine In Preventing Cd4+ Lymphocyte Decline In Patients With Primary Hiv Infection. (One Treatment Arm Receives Placebo)
0.93
0.55
8,031
0.679542
NCT00000770
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Comparative Study Of A Combination Of Zidovudine, Didanosine, And Double-Blinded Nevirapine Versus A Combination Of Zidovudine And Didanosine
0.95
0.74
8,038
0.799752
NCT00000772
listed
ICN Pharmaceuticals, Inc.
ICN Pharmaceuticals
A Phase I Open-Label Study Of The Safety, Tolerance, And Pharmacokinetic Interactions Of Combination Didanosine And Ribavirin In Hiv-Positive Individuals
0.91
0.44
8,031
0.669745
NCT00000781
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, And Triple-Drug Therapy For The Treatment Of Advanced Hiv Disease (Cd4 <= 50/Mm3)
0.95
0.74
8,038
0.799752
NCT00000789
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Comparative Trial Of Zidovudine (Azt) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; D4T) In Children With Hiv Infection
0.95
0.75
8,038
0.803172
NCT00000791
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase Ii Double-Blind Study Of Two Doses Of Sc-49483 In Combination With Zidovudine (Zdv) Versus Zdv
0.93
0.55
8,031
0.723394
NCT00000799
listed
Gilead Sciences
Gilead Sciences
Hpmpc (Cidofovir) Peripheral Cmv Retinitis Trial Protocol
0.94
0.52
4,748
0.69949
NCT00000800
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Methadone Effects On Zidovudine (Zdv, Azt) Disposition
0.92
0.36
731
0.676609
NCT00000807
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
Phase Ii Evaluation Of Low-Dose Oral Etoposide For The Treatment Of Relapsed Or Progressed Aids-Related Kaposi'S Sarcoma After Systemic Chemotherapy
0.93
0.67
242
0.823866
NCT00000811
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Phase Ii/Iii, Double-Blind, Two-Armed Study Of Micronized Atovaquone And Azithromycin (At/Az) As Compared To Trimethoprim-Sulfamethoxazole (Tmp/Smx) In The Prevention Of Serious Bacterial Infections When Used In Children Aged 3 Months To 19 Years With Hiv Infection
0.95
0.67
730
0.82607
NCT00000812
listed
Celgene Corporation
Celgene Corporation
A Phase I, Placebo-Controlled, Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Thalidomide In Subjects With Hiv-1 Infection
0.93
0.58
242
0.766771
NCT00000815
delisted
Merck Sharp & Dohme L.L.C.
Merck Sharp & Dohme LLC
A Phase Ii, Comparative Study Of Seroconversion Of Single-Dose And Two-Dose Measles Vaccination In Hiv-Infected And Hiv-Uninfected Children: A Multicenter Trial Of The Pediatric Aids Clinical Trials Group
0.94
0.61
8,031
0.749617
NCT00000816
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Gradual Initiation Of Trimethoprim/Sulfamethoxazole As Primary Pneumocystis Carinii Pneumonia Prophylaxis
0.92
0.54
830
0.833228
NCT00000819
listed
Upjohn Inc
Upjohn
A Phase Ii Randomized, Double-Blind, Placebo-Controlled Trial To Determine The Efficacy Of Prednisone Therapy In Hiv-Associated Nephropathy (Hivan)
0.93
0.52
1,095
0.75849
NCT00000822
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase I/Ii Double-Blind Controlled Trial To Determine The Safety And Immunogenicity Of Hiv-1 Mn Rgp160 Immuno Ag Vaccine Therapy In Hiv-Infected Individuals With Greater Than Or Equal To 500/Mm3 Cd4+ T Cells And 200-400/Mm3 Cd4+ T Cells
0.93
0.49
8,032
0.676556
NCT00000823
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Multicenter Phase Ii Double-Blind Exploratory Study To Evaluate Differences Among Various Zidovudine/Didanosine Regimens On Quantitative Measures Of Viral Burden In Relatively Early Hiv-1 Infection
0.95
0.74
91
0.864039
NCT00000839
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase I Trial To Evaluate Didanosine (Ddi) In Hiv-Infected Pregnant Women
0.94
0.63
8,032
0.730142
NCT00000953
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Evaluation Of Brovavir ( Bv-Ara-U; Sq 32,756 ) Versus Acyclovir In The Treatment Of Localized Herpes Zoster In Hiv-Infected Patients
0.92
0.6
4,137
0.755093
NCT00000954
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
Phase I/Ii Study Of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) And Dideoxyinosine (Ddi) Or Dideoxycytidine (Ddc) In The Treatment Of Aids-Related Kaposi'S Sarcoma
0.95
0.66
8,032
0.746104
NCT00000955
listed
Warner Lambert Co.
Warner Lambert - Parke Davis
Two-Stage Tuberculin (Ppd) Skin Testing In Individuals With Human Immunodeficiency Virus (Hiv) Infection
0.94
0.56
5,082
0.70337
NCT00000956
listed
Protein Sciences Corp.
Protein Sciences Corporation
A Phase I Multicenter Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160
0.93
0.2
8,038
0.580827
NCT00000960
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase Iii Randomized Placebo-Controlled Trial To Evaluate The Efficacy, Safety And Tolerance Of Oral Zidovudine (Azt) In Pregnant Hiv Infected Women And Their Infants
0.96
0.53
8,032
0.751191
NCT00000961
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase Ii Study To Evaluate The Safety, Tolerance And Efficacy Of Hyperimmune Anti-Hiv Intravenous Immunoglobulin (Hivig) And Of Zidovudine (Zdv) In Infants With Documented Hiv Infections
0.07
0.1
8,038
0.079183
NCT00000963
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Randomized Comparative Trial Of Two Doses Of 2',3'-Dideoxyinosine (Ddi) In Children With Symptomatic Hiv Infection Who Are Either Unresponsive To Zidovudine And/Or Who Are Intolerant To Zidovudine
0.94
0.65
8,032
0.763294
NCT00000965
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Pharmacokinetics Of Total Phosphorylated Zidovudine In Mononuclear Cells From Hiv-Infected Patients
0.53
0.23
615
0.394071
NCT00000967
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Safety And Tolerance Of Zidovudine And Interferon-Alpha In Hiv-Infected Children
0.94
0.55
8,032
0.702779
NCT00000969
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Prospective, Randomized, Open-Label, Comparative Trial Of Dideoxyinosine (Ddi) Versus Dideoxycytidine (Ddc) In Hiv-Infected Patients Who Are Intolerant Of Or Who Have Failed Zidovudine (Azt) Therapy
0.93
0.73
8,038
0.741078
NCT00000973
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
Pyrimethamine Pharmacokinetics In Hiv Positive Patients Seropositive For Toxoplasma Gondii
0.94
0.37
8,038
0.641184
NCT00000975
listed
Janssen Pharmaceutical
Janssen Pharmaceuticals
Pilot Study To Determine The Feasibility Of Itraconazole For Primary Treatment And Suppression Of Relapse Of Disseminated Histoplasmosis In Patients With The Acquired Immunodeficiency Syndrome
0.94
0.53
1,095
0.767611
NCT00000977
listed
Protein Sciences Corp.
Protein Sciences Corporation
Active Immunization Of Asymptomatic, Hiv-Infected Individuals With Recombinant Gp160 Hiv-1 Antigen: A Phase I/Ii Study Of Immunogenicity And Toxicity
0.93
0.19
8,038
0.577351
NCT00000979
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
Comparison Of 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) And Zidovudine In Therapy Of Patients With Hiv Infection
0.93
0.58
1,095
0.779012
NCT00000983
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized Blinded Trial To Evaluate The Safety And Tolerance Of High Versus Low Dose Zidovudine Administered To Children With Human Immunodeficiency Virus
0.95
0.54
1,095
0.776732
NCT00000988
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase I Safety And Pharmacokinetics Study Of Bmy-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily To Patients With Aids Or Aids Related Complex
0.59
0.31
3,220
0.447545
NCT00000989
delisted
Schering-Plough A/S
Schering-Plough
A Controlled, Randomized Phase Ii Study Of The Safety And Efficacy Of Combined Therapy With Ganciclovir And Granulocyte-Macrophage Colony Stimulating Factor Versus Ganciclovir Alone For The Treatment Of Sight-Threatening Cytomegalovirus Retinitis In Aids Patients
0.94
0.56
615
0.740674
NCT00001007
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Multicenter Phase I Trial To Evaluate The Safety And Pharmacokinetics Of Intravenous And Oral Zidovudine In Infants With Perinatal Human Immunodeficiency Virus (Hiv) Exposure
0.93
0.52
3,178
0.713496
NCT00001018
listed
Janssen Pharmaceutical
Janssen Pharmaceuticals
Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics And Dose Escalation, Efficacy, And Safety Study Of Letrazuril For Aids-Related Cryptosporidial Diarrhea
0.92
0.52
2,061
0.716602
NCT00001024
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Multicenter, Open-Label Study Of Viral Burden In Peripheral Blood Versus Lymphoid Tissue Before And After Antiretroviral Therapy In Hiv-Infected Individuals Without Aids (Note: One Arm Receives No Treatment)
0.94
0.67
942
0.77357
NCT00001025
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Study To Evaluate The Short-Term Clinical And Virologic Significance Of Zidovudine Resistance
0.94
0.73
8,035
0.790644
NCT00001029
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Double-Blind, Three-Arm Study Comparing Combination To Monthly Alternating Nucleoside Therapy For The Treatment Of Advanced Hiv Disease (Cd4 <= 50/Mm3) With A Prior History Of Nucleoside Therapy
0.94
0.74
1,095
0.83944
NCT00001035
delisted
Schering-Plough A/S
Schering-Plough
A Phase I Pilot Study Of The Safety And Efficacy Of Interferon Alfa-2B (Ifn Alfa-2B) In Combination With Nucleoside Analog Therapy In Patients With Combined Hepatitis C (Hcv) And Advanced Human Immunodeficiency Virus (Hiv) Infections
0.95
0.53
4,563
0.719349
NCT00001038
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized, Double-Blind Trial Of Valacyclovir Hydrochloride (Bw 256U87) Prophylaxis For Opportunistic Cytomegalovirus End-Organ Disease In Patients With Advanced Hiv Infection (< 100 Cd4+ Lymphocytes)
0.93
0.52
4,137
0.750971
NCT00001045
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Double-Blinded, Randomized Trial Comparing Zidovudine (Azt) Versus Azt Plus Didanosine (Ddi) Versus Azt Plus Ddi Plus Nevirapine In Asymptomatic Patients On Azt Monotherapy Who Develop A Mutation At Codon 215 Of Hiv Reverse Transcriptase In Serum/Plasma Viral Rna
0.95
0.7
8,038
0.78607
NCT00001048
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase Ii Multicenter Study Comparing Antiretroviral Therapy Alone To Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) For The Treatment Of Progressive Multifocal Leukoencephalopathy (Pml) In Human Immunodeficiency Virus (Hiv)-Infected Subjects
0.95
0.66
1,095
0.817777
NCT00001054
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Phase I Trial To Evaluate The Pharmacokinetics, Safety, And Tolerance Of Valacyclovir Hcl In Hiv-1 Infected Children With Herpes Simplex Infections Or Varicella/Zoster Infections
0.09
0.07
8,038
0.054012
NCT00001059
listed
Amgen
Amgen
Comparison Study Of Liposomal Doxorubicin With Or Without Bleomycin And Vincristine For The Treatment Of Advanced Aids-Associated Kaposi'S Sarcoma
0.95
0.64
1,095
0.810936
NCT00001061
listed
Facet Biotech Corporation
Facet Biotech
A Phase Ii, Double-Masked, Randomized, Placebo-Controlled Evaluation Of Standard Therapy Vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (Msl 109) In The Therapy Of Aids Patients With Cytomegalovirus (Cmv) Retinitis
0.96
0.54
8,035
0.737057
NCT00001063
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase Ii Randomized Study Of The Virologic And Immunologic Effects Of D4T Vs Zidovudine Plus D4T Vs Zidovudine Plus Ddl In Hiv-Infected Patients With Cd4 Cell Counts Between 300-600/Mm3 And Greater Than 12 Weeks Zidovudine Experience
0.95
0.65
8,038
0.768968
NCT00001065
listed
BRISTOL MYERS SQUIBB
Bristol-Myers Squibb
A Phase Ii Trial Of Amphotericin B Oral Suspension For Fluconazole-Resistant Oral Candidiasis In Hiv-Infected Patients
0.94
0.67
1,095
0.815497
NCT00001066
listed
GLAXOSMITHKLINE PLC
Glaxo Wellcome
A Randomized Comparative Study Of Combined Zidovudine-Lamivudine (3Tc) Vs. The Better Of Ddi Monotherapy Vs. Zidovudine Plus Ddl In Symptomatic Hiv-1 Infected Children
0.94
0.62
426
0.808386
NCT00001114
delisted
Schering-Plough A/S
Schering-Plough
A Randomized Phase Ii Trial To Determine The Safety, Tolerance, And Efficacy Of Two Doses Of Interferon Alfa-2B Combined With Didanosine In Patients With Kaposi'S Sarcoma
0.94
0.66
8,035
0.766701
NCT00001128
listed
GENETICS INSTITUTE, INC.
Genetics Institute
A Pilot, Proof-Of-Concept, Dose-Escalating Trial Of Recombinant Human Interleukin-12 (Rhil-12) Versus Placebo Along With Paromomycin And Azithromycin For Chronic Cryptosporidiosis In Aids
0.09
0.03
6,176
0.03167
End of preview. Expand in Data Studio

Stocks Weekly PharmaClinicalPredict

Modelled outcome, duration and economic impact for pharmaceutical clinical trials, one row per trial.

91,981 rows, 9 columns. Updated by Papers With Backtest.

Why It Matters

A biotech's value is a probability-weighted pipeline, and the probabilities are what this dataset estimates:

  • Event odds ahead of the readout: success_prediction is a modelled probability that a trial reaches its endpoint. Priced against the sponsor's market capitalisation, it is a view on how much of the outcome is already in the stock.
  • Timing: duration_prediction estimates how long the trial still has to run, which is what decides whether an event is inside or outside a holding period.
  • Size of the move: economic_effect scores how material the trial is to the sponsor, separating a phase III lead asset from a minor indication.

Load It

Installation/Upgrade:

pip install --upgrade pwb-toolbox

Load the Dataset:

from pwb_toolbox import datasets as pwb_ds

predictions = pwb_ds.load_dataset("Stocks-Weekly-PharmaClinicalPredict")
trials = pwb_ds.load_dataset("Stocks-Weekly-PharmaClinicalTrials")

# The predictions carry no ticker; the trial register is what maps them to one.
linked = predictions.merge(
    trials[["trial_id", "symbol", "datetime"]].drop_duplicates("trial_id"),
    on="trial_id",
    how="inner",
)

Columns

Column Name Description
trial_id Registry identifier for the trial. The join key to Stocks-Weekly-PharmaClinicalTrials.
source Registry the trial was read from.
sponsor Sponsoring organisation.
subsidiary Subsidiary running the trial, where it differs from the sponsor.
official_title Registered title of the trial.
success_prediction Modelled probability, between 0 and 1, that the trial meets its endpoint.
success_composite Composite score combining the success model with trial characteristics.
duration_prediction Modelled remaining duration, in days.
economic_effect Unitless index of how material the outcome is to the sponsor.

What This Data Does Not Cover

There is no ticker and no date column. The file is one row per trial, keyed by trial_id, and it carries neither symbol nor datetime. Mapping a prediction to a listed company means joining Stocks-Weekly-PharmaClinicalTrials, which holds both. Anything that needs a point-in-time view has to take its timestamps from that side too.

Access

Browsing the card and the schema is open to anyone. Downloading the files needs an approved request, tied to a subscription: what each plan includes. The same subscription covers the other datasets in this organisation.

Elsewhere

Papers With Backtest publishes 32 datasets on the Hub and codes the papers that use them. Every strategy in the catalogue is run over its own full history before it is published, which is where the numbers above come from.

Downloads last month
78